2008-04-21 23:57:23 -
www.maxygen.com - Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that it will present at the Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, April 30, 2008 at 3:00 p.m. Eastern Time. Russell Howard, Maxygen's chief executive officer, will present. A live webcast of the presentation can be
accessed on Maxygen's website at www.maxygen.com/webcasts. A replay of the presentation will be available for 30 days.
About Maxygen
Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. The company's lead program, MAXY-G34, is designed to be an improved version of long-acting G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in Maxygen's pipeline is a new Factor VIIa product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of rheumatoid arthritis. Maxygen uses its proprietary DNA shuffling technology and extensive protein modification expertise to pursue the creation of biosuperior proteins. www.maxygen.com
Maxygen, Inc.
Michele Boudreau, Investor and Public Relations
650-279-2088
michele.boudreau@maxygen.com 
